Horizon takes hostile Depomed bid directly to shareholders
Horizon Pharma is pushing ahead with its hostile, $2.4-billion bid to buy Depomed by starting an offer to exchange a portion of its stock for shares of the rival drugmaker.
Sep 8, 2015
0
4